Bristol Myers Squibb (BMY) Non-Current Assets (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Non-Current Assets for 18 consecutive years, with $59.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 3.9% year-over-year to $59.1 billion in Q2 2026; TTM through Jun 2026 was $240.2 billion, a 4.49% decrease from a year earlier, with the FY2025 full-year figure at $60.6 billion, down 3.46% from the prior year.
• Non-Current Assets was $59.1 billion for Q2 2026 at Bristol Myers Squibb, roughly flat from $59.3 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $72.9 billion in Q1 2022 and troughed at $59.1 billion in Q2 2026.
• A 5-year average of $65.2 billion and a median of $64.5 billion in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets decreased 14.55% in 2022 and grew 4.71% in 2024, its largest moves.
• Over 5 years, Non-Current Assets stood at $69.5 billion in 2022, then dropped by 8.85% to $63.4 billion in 2023, then dropped by 0.89% to $62.8 billion in 2024, then dropped by 3.46% to $60.6 billion in 2025, then retreated by 2.63% to $59.1 billion in 2026.
• The last three Non-Current Assets figures came in at $59.1 billion (Q2 2026), $59.3 billion (Q1 2026), and $60.6 billion (Q4 2025), per Business Quant data.